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Objectives The aim of this study was to compare Friedewald-estimated and directly measured low-density lipoprotein cho-
lesterol (LDL-C) values.
Background LDL-C is routinely estimated by the Friedewald equation to guide treatment; however, compatibility with direct mea-
surement has received relatively little scrutiny, especially at levels70 mg/dl now targeted in high-risk patients.
Methods We examined 1,340,614 U.S. adults who underwent lipid profiling by vertical spin density gradient ultracentrifu-
gation (Atherotech, Birmingham, Alabama) from 2009 to 2011. Following standard practice, Friedewald LDL-C
was not estimated if triglyceride levels were 400 mg/dl (n  30,174), yielding 1,310,440 total patients and
191,333 patients with Friedewald LDL-C 70 mg/dl.
Results Patients were 59  15 years of age and 52% were women. Lipid distributions closely matched those in the Na-
tional Health and Nutrition Examination Survey. A greater difference in the Friedewald-estimated versus directly
measured LDL-C occurred at lower LDL-C and higher triglyceride levels. If the Friedewald-estimated LDL-C was
70 mg/dl, the median directly measured LDL-C was 9.0 mg/dl higher (5th to 95th percentiles, 1.8 to 15.4
mg/dl) when triglyceride levels were 150 to 199 mg/dl and 18.4 mg/dl higher (5th to 95th percentiles, 6.6 to
36.0 mg/dl) when triglyceride levels were 200 to 399 mg/dl. Of patients with a Friedewald-estimated LDL-C
70 mg/dl, 23% had a directly measured LDL-C 70 mg/dl (39% if triglyceride levels were concurrently 150 to
199 mg/dl; 59% if triglyceride levels were concurrently 200 to 399 mg/dl).
Conclusions The Friedewald equation tends to underestimate LDL-C most when accuracy is most crucial. Especially if triglyc-
eride levels are 150 mg/dl, Friedewald estimation commonly classifies LDL-C as 70 mg/dl despite directly
measured levels 70 mg/dl, and therefore additional evaluation is warranted in high-risk patients. (J Am Coll
Cardiol 2013;62:732–9) © 2013 by the American College of Cardiology FoundationLow-density lipoprotein cholesterol (LDL-C), as estimated
by the Friedewald equation in routine patient care, is a
central focus of clinical practice guidelines throughout the
world, including in the United States (1–3), Europe (4), and
Canada (5). The Friedewald equation estimates LDL-C as total
cholesterol minus high-density lipoprotein cholesterol (HDL-C)
minus triglycerides/5 in milligrams per deciliter (6). The equation
was introduced into clinical practice in 1972 because of the
additional time and financial costs associated with ultracentrifu-
gation to directly measure LDL-C (6).
See page 740
Friedewald et al. (6) recognized in their original paper
that “simple division of the plasma triglyceride by five does
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Abbott Laboratories, Aegerion, Amgen, Amylin, AstraZeneca, GlaxoSmithKline,
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Director; and receives royalty from the University of Alabama in Birmingham. Dr.
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reported that they have no relationships relevant to the contents of this paper to
disclose.Manuscript received November 15, 2012; revised manuscript received January 14,
2013; accepted January 14, 2013.not give a very accurate estimate of very low-density
lipoprotein cholesterol.” A central idea in the development
of the Friedewald equation was that inaccuracy in very low
density lipoprotein cholesterol (VLDL-C) could be toler-
ated because the VLDL-C concentration was small relative
to LDL-C (6). However, this issue must be reevaluated in
the contemporary treatment era wherein much lower
LDL-C levels are sought (1–5) and hypertriglyceridemia is
a greater problem due to epidemics of obesity, insulin
resistance, and diabetes mellitus (7). Although previous
reports suggest underestimation of LDL-C by the Friede-
wald equation at low LDL-C levels (8–10) and high
triglyceride levels (10,11), the equation has remained in
routine use with remarkably little scrutiny.
Therefore, in the largest study of its kind to date (2,925
times larger than the original Friedewald dataset), we
examined Friedewald estimation of LDL-C relative to
direct measurement by vertical spin density gradient ultra-
centrifugation. We investigated the potential importance of
differences between the 2 methods in clinical decision
making by comparing treatment classification according to
worldwide clinical practice guidelines.
Methods
Study population. We examined consecutive lipid profiles
from a clinical sample of 1,340,614 U.S. adults (18 years of
age and older) who underwent vertical spin density gradient
ultracentrifugation of cholesterol by the Vertical Auto
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nostics Lab, Birmingham, Ala-
bama) from 2009 to 2011. Con-
secutive denotes that the first
available lipid profile for each pa-
tient was examined. The present
report focuses on Friedewald-
estimated versus directly mea-
sured LDL-C; therefore, we ex-
cluded patients with triglyceride
levels 400 mg/dl (n  30,174;
2.3% of sample) due to known
limitations of Friedewald estima-
tion in such individuals (6). This
yielded a study sample of 1,310,440 patients for analysis. We
determined a priori based on the characteristics of the Friedewald
equation and previous literature that our analysis would focus on
patients with Friedewald-estimated LDL-C levels of 70 to 99
mg/dl (n 376,323) and particularly those with levels70 mg/dl
(n  191,333), as targeted in high-risk patients (1–5).
ipid measurements. Inverted rate zonal, single vertical
pin, density gradient ultracentrifugation by the VAP tech-
ique allowed direct measurement of LDL-C, VLDL-C,
ntermediate-density lipoprotein cholesterol, lipoprotein(a)
holesterol, and HDL-C (12). VAP accuracy was examined by
Figure 1 Lipid Distributions in Study Sample and NHANES
Kernel density plots of lipid parameters in study sample (Very Large Database of Lipid
2007 to 2008. HDL-C  high-density lipoprotein cholesterol; IQR  interquartile range
Abbreviations
and Acronyms
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
NHANES  National Health
and Nutrition Examination
Survey
VAP  Vertical Auto Profile
VLDL-C  very low density
lipoprotein cholesterolearly (2007 to 2012) random split sample comparison
n  330; LDL-C range, 25 to 239 mg/dl; 107  37 mg/dl)
ith beta quantification at Washington University’s Core
aboratory for Clinical Studies (St. Louis, Missouri), a refer-
nce laboratory for lipoprotein analysis (r  0.973, bias 
.1%). Triglycerides were directly measured using the Abbott
RCHITECT C-8000 system (Abbott Laboratories, Abbott
ark, Illinois) and were compared with the University of
labama School of Medicine (Birmingham, Alabama) labora-
ory (n 40, r 0.997, bias0.05%). Overall, the analytical
erformance of lipid measurements met guideline-established
enchmarks and are further detailed in the Online Appendix (13).
ata management. Raw individual patient data were elec-
ronically downloaded at Atherotech Diagnostics Labora-
ory, cleaned of duplicates, then de-identified and trans-
erred in aggregate to the senior investigator of this study.
he master database, named the Very Large Database of
ipids, is housed at The Johns Hopkins Hospital in
altimore, Maryland. This is the Very Large Database of
ipids (VLDL). The Johns Hopkins Institutional Review
oard declared the study exempt. The study is registered on
linicaltrials.gov (NCT01698489).
tatistical methods. We sought to assess whether lipids
n our sample were representative of the general adult
opulation. To test this, we generated kernel density
9 to 2011) and the National Health and Nutrition Examination Survey (NHANES)
 low-density lipoprotein cholesterol.s, 200
; LDL-C
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our database and recent lipid data from the National
Health and Nutrition Examination Survey (NHANES)
2007 to 2008 (14). We examined NHANES subjects who
were 18 years of age and older with triglyceride levels
400 mg/dl (n  2,679).
Friedewald LDL-C was estimated as total cholesterol
minus HDL-C minus triglycerides/5 in milligrams per
deciliter. Direct LDL-C was subtracted from Friedewald-
estimated LDL-C to determine the absolute difference in
their values in milligrams per deciliter. The definition of
LDL-C by the Friedewald equation and by direct measure-
ment was the same, non–HDL-C minus VLDL-C, repre-
senting the sum of cholesterol carried by biochemically
defined LDL (real LDL, LDLr), intermediate-density li-
poprotein, and lipoprotein(a) subfractions (for additional
discussion, see the Online Appendix, LDL-C definitions).
Direct and Friedewald-estimated LDL-C values were
classified as70 mg/dl or 70 to 99 mg/dl as emphasized for
high-risk patients in worldwide clinical practice guidelines
(1–5) with the same 30-mg/dl increment used to define
higher groups up to 190 mg/dl. Reclassification was
defined as present when direct LDL-C classified a patient
within a higher (upward) or lower (downward) treatment
group compared with Friedewald-estimated LDL-C.
Statistical analyses of numerical data and kernel density
plots were performed in Stata version 11.0 (StataCorp LP,
College Station, Texas), bar charts were created in Mi-
crosoft Excel 2010 (Microsoft, Redmond, Washington),
and logarithmically scaled pseudocolor-encoded data den-
sity plots were generated in R Version 2.14.1 (Foundation
for Statistical Computing, Vienna, Austria).
Results
Study sample. Patients were 59  15 years of age and
evenly distributed by sex (52% women). Distributions of
total cholesterol, HDL-C, triglycerides, and Friedewald-
estimated LDL-C in our study sample closely matched
those in the NHANES (Fig. 1). The median directly
measured LDL-C was 109 mg/dl (interquartile range: 85 to
135 mg/dl; 112 38 mg/dl; full range: 2 to 1077 mg/dl). In
random subsample with additional clinical laboratory data
n  3,107), the median hemoglobin A1c was 5.7% (inter-
uartile range: 5.5% to 6.1%), median high-sensitivity
-reactive protein level was 1.8 mg/l (interquartile range:
.8 to 4.4 mg/l), and median estimated glomerular filtration
ate was 67.4 ml/min/1.73 m2 (interquartile range: 49.3 to
84.1 ml/min/1.73 m2) (for additional details, see Online
able 1).
mpact of low LDL-C and high triglyceride levels on
riedewald-estimated versus directly measured LDL-C.
t low Friedewald-estimated LDL-C levels, particularly
hose 100 mg/dl, Friedewald-estimated LDL-C was typ-
cally lower than directly measured LDL-C (Figs. 2A and 2B). A
reater absolute difference in Friedewald-estimated ver- Lus directly measured LDL-C occurred at higher triglyc-
ride concentrations (Online Fig. 1). Differences between
riedewald-estimated and directly measured LDL-C
ere compatible with differences in the estimation of
LDL-C as triglycerides/5 by the Friedewald equation
ompared with direct VLDL-C measurement (Online
ig. 2).
Comparing Friedewald-estimated and directly mea-
ured LDL-C in patients with Friedewald-estimated
DL-C levels in the 2 lowest groups, those with higher
riglyceride levels had greater median differences and
ithin-group variance (Fig. 3A). If Friedewald-estimated
DL-C was 70 mg/dl, the median directly measured
Figure 2 Impact of LDL-C Level on Absolute Difference in
Friedewald-Estimated and Directly Measured LDL-C
Absolute difference (Friedewald  direct LDL-C) across Friedewald-estimated
LDL-C levels in the full study sample of 1,310,440 adults (A) and 567,656
adults with Friedewald-estimated LDL-C 100 mg/dl (B). The density of data is
expressed by different shades of color, which represent increasing densities of
patients per pixel, from light blue to purple. Color pixels below the dark hori-
zontal line represent cases in which Friedewald-estimated LDL-C is lower than
directly measured LDL-C and vice versa for color pixels above the line. LDL-C 
low-density lipoprotein cholesterol.DL-C was 9.0 mg/dl higher (5th to 95th percentiles,
736 Martin et al. JACC Vol. 62, No. 8, 2013
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199 mg/dl and 18.4 mg/dl higher (5th to 95th percen-
tiles, 6.6 to 36.0 mg/dl) when triglyceride levels were 200
to 399 mg/dl.
Treatment group reclassification by directly measured
LDL-C. Overall, 191,563 patients (14.6%) were reclassi-
fied by directly measured LDL-C, which was largely due to
upward reclassification into a higher LDL-C treatment
group (n  147,759; 11.3%). Treatment group reclassifica-
tion primarily occurred in patients in lower LDL-C and
higher triglyceride level groups (Table 1).
Reclassification was more frequent in patients with low
LDL-C and concurrently high triglyceride levels (Figs.
3B and 3C). Of patients with Friedewald-estimated
LDL-C 70 mg/dl, 23% had a directly measured
LDL-C 70 mg/dl (39% if triglyceride levels are con-
currently 150 to 199 mg/dl; 59% if triglyceride levels are
concurrently 200 to 399 mg/dl).
Discussion
The most important finding of our study is that the
Friedewald equation tends to underestimate LDL-C
most when accuracy is most crucial. Particularly in the
Figure 3 Absolute Difference in Friedewald-Estimated and Direc
LDL-C Levels in the Treatment Range for High-Risk
(A) Absolute difference (Friedewald  direct LDL-C) in Friedewald-estimated LDL-C
groups (each assigned a color, as depicted). Proportion reclassified by direct LDL-
or 70 mg/dl (C). LDL-C  low-density lipoprotein cholesterol (B) or 70 mg/dl (Cpresence of triglyceride levels 150 mg/dl, LDL-Cunderestimation is sufficient to generate considerable
reclassification by direct LDL-C with respect to the
high-risk treatment target of 70 mg/dl. Our study is by
far the largest to date to examine the Friedewald estima-
tion of LDL-C relative to direct measurement, 2,925
times larger than the original Friedewald dataset, with
approximately 1 in every 180 U.S. adults represented. In
this contemporary sample, we used a different laboratory
methodology than that used in previous studies and had
simultaneous access to direct LDL-C and VLDL-C data.
Friedewald equation: development and potential limitations.
Now widely applied, the Friedewald equation was origi-
nally developed for use in patients with familial dyslipi-
demia or their relatives to distinguish Fredrickson-Levy
dyslipidemias (6). The Friedewald equation performs
remarkably well considering this context and its deriva-
tion in 448 subjects. However, as shown in our study and
previous smaller studies (8 –11) and as cautioned in the
original Friedewald et al. paper (6), material differences
between Friedewald-estimated and directly measured
LDL-C may arise at lower LDL-C and higher triglyc-
eride concentrations because VLDL-C estimation con-
stitutes a relatively larger portion of the equation. Nota-
easured LDL-C by Triglyceride Strata at
nts and Treatment Group Reclassification
s of 70 to 99 mg/dl and 70 mg/dl with substratification into 4 triglyceride
edewald–estimated LDL-C was 70 to 99 mg/dl (B)
-C low-density lipoprotein cholesterol. Continued on the next page.tly M
Patie
group
C if Fri
). LDLbly, the lowest LDL-C concentrations, where we observe
e
n
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estimated versus directly measured LDL-C, fall at the
low end or outside of the distribution in the original
training dataset used in the 1972 Friedewald analysis.
The 400 mg/dl triglyceride criterion for the Friedewald
quation is widely known, and indeed 2% of our sample was
ot eligible for LDL-C estimation for this reason. However,
ther potential limitations of the equation have received
emarkably little scrutiny despite the equation’s status as an
mportant paradigm in medicine for40 years. Modifications
to the Friedewald equation have been proposed (15), but not
widely adopted, and such approaches are limited by variance
in the triglyceride-to-VLDL-C ratio.
Although we are not suggesting routine clinical mea-
Figure 3 Continuedsurement of LDL-C by direct assays, it bears mentioningthat multiple direct assays beyond the VAP test are
available. Nevertheless, non–HDL-C and apolipoprotein
B are alternative approaches, with potential advantages
over any measure of LDL-C, and these measures avoid
confusion that arises in defining LDL-C (conventional
definition used in this study and most clinical trials versus
biochemically defined LDL-C; see Online Appendix,
LDL-C Definitions) (2). Moreover, in clinical trial
patients with Friedewald-estimated LDL-C levels in the
high-risk treatment target of 70 mg/dl highlighted in
our study, non–HDL-C and apolipoprotein B were
stronger markers of residual risk than Friedewald-
estimated LDL-C (16). Additional discussions of non–
HDL-C and apolipoprotein B are available elsewhere
(4,5,17).
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tially far-reaching implications for patient care. As many as
85% of U.S. adults reported having undergone lipid testing
in a 2009 Centers for Disease Control and Prevention
telephone survey (18). Indeed, worldwide guidelines recom-
mend Friedewald-estimated LDL-C assessment every 3 to
5 years for screening and at least every 6 to 12 months for
treatment monitoring (1–5). Guidelines in Europe (4) and
Canada (5) assign the highest level of evidence (Class IA) to
LDL-C treatment goals. Considering these treatment
goals, we highlight that discordance in classification be-
tween Friedewald-estimated and directly measured LDL-C
is more common at low LDL-C levels (e.g., when the
clinical question is whether a patient has a LDL-C level
70 mg/dl).
Study limitations. Although patients undergoing VAP
testing may be a special population, lipid distributions in our
sample closely match those in a nationally representative
sample. We do not have access to detailed clinical charac-
teristics of patients in our sample or clinical outcomes;
treatment groupings and potential implications are inferred
on the basis of the lipid profile only. It is unknown whether
patients in our sample were receiving statin therapy; in the
NHANES adults analyzed, 5% were taking a statin. We
found similar results in pediatric patients in whom statin
therapy is less likely (Online Appendix, Pediatric Results).
Moreover, Friedewald-estimated LDL-C is used in daily
clinical practice for patients on and off statins.
Although some study samples may have been acquired
in nonfasting states, this is compatible with clinical
practice, and results similar to ours have been obtained in
smaller, completely fasting samples (8,9). In addition, our
study examines one-time LDL-C measurement. Al-
though commonly used for clinical decision making,
guidelines also support serial measurements to establish
Reclassification by Directly Measured LDL-C inStrata of Friedewald-Estimated LDL-C andTrig yceride Levels
Table 1
Reclassification by Directly Measured LDL-C in
Strata of Friedewald-Estimated LDL-C and
Triglyceride Levels
Concordant
(n  1,118,877)
Reclassified
(n  191,563)
Friedewald-estimated
LDL-C, mg/dl
190 35,482/38,435 (92.3) 2,953/38,435 (7.7)
160–189 81,713/93,669 (87.2) 11,956/93,669 (12.8)
130–159 208,017/235,722 (88.2) 27,705/235,722 (11.8)
100–129 327,497/374,958 (87.3) 47,461/374,958 (12.7)
70–99 318,572/376,323 (84.7) 57,751/376,323 (15.3)
70 147,596/191,333 (77.1) 43,737/191,333 (22.9)
Triglyceride levels, mg/dl
100 485,466/520,880 (93.2) 35,414/520,880 (6.8)
100–149 358,791/398,174 (90.1) 39,383/398,174 (9.9)
150–199 163,723/204,145 (80.2) 40,422/204,145 (19.8)
200–399 110,897/187,241 (59.2) 76,344/187,241 (40.8)
Values shown are n/N in group (%).
LDL-C  low-density lipoprotein cholesterol.greater accuracy or assess the change in LDL-C withintervention (1–5). Finally, guideline cutpoints for
LDL-C are based on population averages using mostly
Friedewald-estimated data. Rather than challenging
population-averaged cutpoints, this report illuminates
the considerable discordance that may occur from 1
patient to the next in Friedewald-estimated versus di-
rectly measured LDL-C.
Conclusions
The Friedewald equation tends to underestimate LDL-C levels in
the setting of high triglyceride levels, especially at low LDL-C
levels, which could result in undertreatment of high-risk patients.
Based on these results, high-risk patients should have additional
evaluation, especially if triglyceride levels are150 mg/dl. Under-
estimation in Friedewald-estimated LDL-C warrants consider-
ation in contemporary patient care, as clinicians care for patients,
as experts formulate clinical practice guidelines, and as investiga-
tors design future research studies.
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